PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others. It also trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, consumable products for hemodialysis therapy, pharmaceutical, medical equipment, and food and beverage; prescription and non-prescription medicines; veterinary products; and operates drug stores, health care clinics, and hemodialysis clinic. In addition, the company provides dental and other equipment; calibration services; distribution and logistics for consumer goods that require cold room temperature handling; transportation and warehousing service using digital platform; information services through web portals and/or digital platforms; healthcare services; end-to-end value added services; and logistic services, including chiller, cool, and ambient rooms, as well as container chiller. Further, it offers EMOS, a business-to-business (B2B) platform that offers pharmaceuticals and consumer health products; and MOSTRANS, an intelligent logistics platform that connects with shippers, transporters, and receivers. The company was formerly known as PT Arya Gupta Cempaka and changed its name to PT Enseval Putera Megatrading Tbk. in August 1993. PT Enseval Putera Megatrading Tbk. was founded in 1973 and is headquartered in Jakarta Timur, Indonesia. PT Enseval Putera Megatrading Tbk. is a subsidiary of PT Kalbe Farma Tbk.
Metrics to compare | EPMT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEPMTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.0x | 19.5x | −0.4x | |
PEG Ratio | 1.26 | 0.45 | 0.00 | |
Price/Book | 0.8x | 2.0x | 2.6x | |
Price / LTM Sales | 0.2x | 2.3x | 3.2x | |
Upside (Analyst Target) | - | 24.2% | 51.4% | |
Fair Value Upside | Unlock | 11.3% | 6.7% | Unlock |